FDA Clears Patient-Powered Matrix for Chronic Wound Healing

HACKENSACK, N.J. – April 07, 2026 – The U.S. Food and Drug Administration (FDA) has cleared a novel medical device that creates a living, patient-specific bandage from a small sample of blood, offering new hope for millions suffering from chronic, non-healing wounds. Royal Biologics, a leader in regenerative medicine, announced it received clearance for its Fibrinet® PRF Wound Matrix, a point-of-care system designed to manage persistent cutaneous wounds like diabetic and venous ulcers.

The clearance marks a significant milestone in the shift towards personalized medicine, leveraging the body's own healing capabilities to tackle conditions that have long challenged the healthcare system. For patients with debilitating wounds that can persist for months or years, this technology represents a potential breakthrough that is both autologous—derived from the patient's own body—and can be prepared and applied directly at the bedside.

The Science of Self-Healing

At the heart of the Fibrinet® system is Platelet-Rich Fibrin Matrix (PRFM) technology. The process is elegantly simple in its workflow: a clinician draws a small amount of the patient’s blood, processes it through a two-step centrifugation, and within minutes creates a durable, suturable fibrin matrix. This matrix is a concentration of the patient's own intact platelets, white blood cells, and the growth factors essential for tissue repair, all suspended within a natural fibrin scaffold.

Unlike earlier generations of platelet-rich plasma (PRP), which often require the use of external activators like bovine thrombin to induce clotting, the Fibrinet® system creates the PRFM without such additives. This is a key distinction, as it allows for a slower, more natural polymerization of fibrin, resulting in a matrix structure that more closely resembles the body's own clots.

"We are very excited to announce the FDA approval of Fibrinet® PRF Wound Matrix," said Salvatore Leo, CEO and founder of Royal Biologics, in the company's announcement. He noted the system "enables the delivery of autologous platelets and associated growth factors within a fibrin scaffold."

This scaffold serves a triple function in the wound bed. First, it provides a physical structure—the scaffold itself—that gives new cells a framework to grow upon. Second, it delivers crucial biological signals, as the entrapped platelets gradually release a cocktail of growth factors for up to seven days, according to preclinical models. These signals are vital for promoting angiogenesis (the formation of new blood vessels) and recruiting the body's repair cells to the site. Finally, the matrix retains the patient's own viable cells, primarily platelets, ensuring sustained biological activity over time.

Clinical Promise and Published Data

The potential of this technology is supported by emerging clinical data. In a prospective study on chronic diabetic foot ulcers by Fridman & Wielgomas, the use of PRFM technology demonstrated significant healing. Observational data associated with the technology showed that 92% of wounds achieved a reduction in size of at least 50% at 12 weeks, with 57% achieving complete closure. The mean time to heal for those who reached complete closure was approximately 6.75 weeks.

Another foundational study by Lucarelli et al. in 2010 characterized the robust mechanical properties of the Fibrinet matrix and its sustained release of key growth factors, concluding it was a promising tool for accelerating tissue repair.

While these results are encouraging, some experts in the broader field of regenerative medicine note that the evidence for PRF technologies, while growing, has been marked by clinical heterogeneity in studies. Systematic reviews have pointed out the difficulty in comparing results across different preparation methods and wound types, calling for more standardized, large-scale clinical trials to definitively establish PRF's role as a first-line treatment. However, the existing evidence strongly suggests that PRF is safe, can be performed in an outpatient setting, and holds significant potential to improve outcomes where standard care has failed.

Navigating the Regulatory and Reimbursement Maze

Perhaps the most immediate and impactful aspect of the Fibrinet® clearance is its strategic alignment with U.S. reimbursement policies. The Centers for Medicare & Medicaid Services (CMS) maintains a National Coverage Determination (NCD 270.3) that governs the use of platelet-based therapies for chronic wounds. This policy explicitly states that coverage is available for PRP-derived treatments when they are "prepared using devices with Food and Drug Administration (FDA)-cleared indications for the management of exuding cutaneous wounds, such as diabetic ulcers."

This specific language has created a high bar for manufacturers. While many PRP devices are on the market for orthopedic or aesthetic uses, Royal Biologics notes that Fibrinet® is among a select few that have secured the specific FDA indication for wound management that unlocks the door to CMS coverage. This regulatory and reimbursement alignment is critical for widespread adoption, as it gives hospitals and clinics a clear pathway to be paid for providing the therapy. Without it, even the most innovative technologies can languish due to cost concerns.

A New Player in the Advanced Wound Care Market

With this clearance, Royal Biologics is positioning Fibrinet® as a disruptive force in the multi-billion dollar advanced wound care market. The company is directly challenging what its CEO calls an "overabundance of commoditized skin substitute options." Many of these substitutes are allogeneic (derived from donor tissue) or xenogeneic (derived from animals) and come with their own complexities, including high costs and potential for immune response.

Fibrinet® enters the market as a "unique, patient specific solution," offering an advanced live cellular therapy at the point of care. The system is available in two kit sizes to treat wounds up to 12 cm², making it adaptable to various clinical needs.

Royal Biologics plans to officially launch the product at the upcoming National Symposium for Advanced Wound Care (SAWC) in Charlotte, North Carolina, where clinicians will have their first opportunity to see the system firsthand. This launch signals a new chapter not only for the company but also for the broader trend of personalized, regenerative medicine being brought directly to the patient's bedside to solve some of healthcare's most persistent and costly problems.

The move from generalized treatments to highly personalized, autologous solutions like the Fibrinet® PRF Wound Matrix represents a fundamental shift in medical thinking, where the most powerful pharmacy may ultimately reside within the patient.